Chemically Modified AAV Capsids for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adeno-associated virus (AAV) vectors face limitations in gene therapy due to immunogenicity, tissue proliferation, and broad tropism, leading to reduced therapeutic efficacy and increased immune response, particularly in pediatric patients, and require high doses to achieve effective transduction, which can induce neutralizing antibodies and off-target effects.
Innovation Solution
Chemical modification of AAV capsids, specifically modifying tyrosine residues with aryl diazonium salts and 4-phenyl-1,2,4-triazole-3,5-dione (PTAD) moieties, to alter antigenicity, tropism, and immunoreactivity, allowing for targeted cell-specific ligands and reduced proteasome degradation, thereby enhancing transduction efficiency and reducing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high doses of AAV are administered to achieve effective transduction, then transduction efficiency is improved, but immune response and neutralizing antibody induction increase
Solution Approach 1:
The patent applies local quality by modifying specific tyrosine residues at particular locations on the AAV capsid surface (e.g., T34, T39, T166, T171, T463, T468) while leaving other regions unchanged. This localized chemical modification approach allows optimization of immune evasion at specific epitopes without altering the overall capsid structure or function, thereby achieving effective transduction at lower doses with reduced immune response.
2Productivity
If AAV vectors are re-administered to treat diseases, then therapeutic effect is improved, but neutralizing antibodies from first administration prevent transduction
Solution Approach 1:
The patent employs parameter changes by chemically modifying tyrosine residues on the AAV capsid surface, which alters the physical-chemical properties of the viral particle. This modification changes the antigenic parameters of the capsid, allowing the vector to evade pre-existing neutralizing antibodies from previous administrations. The chemical modification transforms the capsid's interaction with the immune system while maintaining its transduction function, enabling re-administration for sustained therapeutic effect.
3Ease of manufacture
If AAV capsid proteins are left unmodified, then vector production is simplified, but proteasome-mediated degradation reduces transduction efficiency
Solution Approach 1:
The patent applies the taking out principle by removing the problematic phosphorylation modification that occurs naturally on tyrosine residues. By chemically blocking these tyrosine residues, the patent extracts or removes the degradation pathway from the system. The modified capsids are no longer substrates for proteasome-mediated degradation, thereby eliminating this loss mechanism while maintaining simple production processes.
4Area of stationary object
If AAV vectors are administered systemically, then broad tissue coverage is achieved, but neutralizing antibodies completely prevent transduction in target tissue
Solution Approach 1:
The patent converts the harmful effect of pre-existing neutralizing antibodies into a beneficial opportunity by designing capsids that are specifically engineered to evade these antibodies. The chemical modification of tyrosine residues transforms the capsid into a form that is no longer recognized by existing antibodies, thereby converting the previously harmful immune response into a non-interfering state that allows successful transduction even in the presence of pre-existing immunity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chemical modification of AAV capsids results in increased transduction efficiency, reduced immune response, and improved tropism, enabling more effective and targeted gene delivery with lower doses, while maintaining capsid integrity and infectivity.
Implementation Method 1
Chemical modification of AAV capsids, specifically modifying tyrosine residues with aryl diazonium salts and 4-phenyl-1,2,4-triazole-3,5-dione (PTAD) moieties
Data Source
Figure 1~2B
Figure 3~4C
Figure 5~6C
AI summary
The invention relates to chemically modified adeno-associated (AAV) virus and their use in gene therapy.